spacer
home > epc > spring 2002 > drug information association's 14th annual euromeeting - basel, switzerland, 5th-8th march 2002
PUBLICATIONS
European Pharmaceutical Contractor

Drug Information Association's 14th Annual EuroMeeting - Basel, Switzerland, 5th-8th March 2002

The 14th annual DIA EuroMeeting is based on the premise that in the 21st Century only a relatively small proportion of all diseases can be adequately treated, nevermind cured. At a fundamental level there is a lack of understanding of the mechanism of disease - particularly the genetic basis of disease and its implications for rational drug treatment.

Of equal concern is that only a small proportion of all patients have access to safe medicinal products at affordable prices. The availability of safe and effective medicines is a real issue in third world countries where for many patients the cost of diagnosis and treatment are beyond their means. This leads to counterfeit and often dangerous substitutes being sold in those countries. Where treatments are available there is often a lack of clear information on the products and their rational use.

Regulatory authorities, government health departments and medical insurance companies add their own particular and specific hurdles to the early availability of effective treatments.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Richard Barrett of Pfizer Global Research and Development, UK

Richard Barrett of Pfizer Global Research and Development, UK is the Co-Chairperson of the Euro2002 Programme Committee, along with Manuel Zahn, of AstraZeneca, Sweden.
spacer
Richard Barrett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Partners with Propeller Health to Gather Accurate Data on Asthma and COPD Medication Use

Philadelphia, PA – January 07, 2020: Signant Health announced today a partnership to connect TrialMax®, the industry-leading electronic Clinical Outcome Assessment (eCOA) platform, to Propeller Health’s digital health platform for asthma and COPD (chronic obstructive pulmonary disease).
More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement